Summit Therapeutics completes initial dosing trials on muscular dystrophy drug 1 234 567

Summit Therapeutics completes initial dosing trials on muscular dystrophy drug

livecharts.co.uk

Biopharmaceutical company Summit Therapeutics has completed an initial 24-week phase 2 clinical dosing trial of Ezutromid, its orally administered small molecule utrophin modulator, in patients with Duchenne muscular dystrophy (DMD).

Full news

Share:

More:

1 234 567

1 234 567

1 234 567

1 234 567

1 234 567

1 234 567